We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
As with any medicine, the MHRA will keep the safety and effectiveness of Nirogacestat hydrobromide under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of lenacapavir under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of fluticasone propionate under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of mirdametinib under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of concizumab under close review.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16th September 2025, approved the medicine vorasidenib (Voranigo).
As with any medicine, the MHRA will keep the safety of gepotidacin under close review.
As with any medicine, the MHRA will keep the safety of zuranolone under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of teplizumab under close review.
New measures to crack down on cowboy cosmetic procedures will be introduced by the government.
The approval is supported by a study involving 453 adults with advanced platinum-resistant cancers of the ovary, fallopian tubes and the peritoneum that were FRα positive
New genetic therapy approved for SOD1-ALS brings targeted treatment option to patients in the UK
Ensuring the seasonal flu vaccine is ready, safe and effective involves months of international planning, testing and collaboration
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 18 July 2025, approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as …
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flus…
The new Business Plan sets out priorities for 2025–26: Protecting public safety and maintaining public trust; delivering efficient, predictable services through regulatory excellence; being an agile organisation that drives …
As with all products, we will keep its safety under close review
This is a precautionary measure while the MHRA conducts the safety review.
Anyone who suspects that they’ve had an adverse reaction to their weight loss or diabetes medicine or suspects it is not a genuine product, should report it to the MHRA.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).